title: Establishment and characterization of an IGSK-2 cell line derived from ascitic fluid of recurrent hCG and somatostatin secreted adenocarcinoma of the stomach.
abstract: We examined a 32-year-old Japanese man who was clinically diagnosed with gastric cancer, type 4, and histopathologically diagnosed with mucinous and poorly differentiated adenocarcinoma (mucinous > poorly) of the stomach. We successfully established and characterized a cell line (designated as IGSK-2) derived from the ascitic fluid of the patient with recurrent and cisplatin-resistant carcinoma. The IGSK-2 cells grew in multi-layered culture in culture dishes. The cells secreted 18 pg/mL somatostatin, 9.1 mIU/mL human chorionic gonadotrophin (hCG), 8000 U/mL carbohydrate antigen 19-9 and 410 ng/mL carcinoembryonic antigen over 4 days of culture. The population doubling time was approximately 83 h. The susceptibility test of anticancer drugs revealed that IGSK-2 cells were sensitive to Taxol, but were not sensitive to cisplatin, 5-fluorouracil and irinotecan. Immunohistochemical staining revealed that the IGSK-2 cells were positive against antihCG antibody and antiserotonin antibody, and negative against antisomatostatin antibody and antigastrin antibody.
authors.affiliation: Department of Anatomy II, Jikei University School of Medicine, 3-25-8 Nishi-shinbachi, Minato-ku, Tokyo 105-8461, Japan. satoshi-ohi@jikei.ac.jp
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ohi
authors.forename: Naoto
authors.initials: N
authors.lastname: Takahashi
authors.forename: Hisashi
authors.initials: H
authors.lastname: Hashimoto
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Tachibana
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Hirabayashi
authors.forename: Kayoko
authors.initials: K
authors.lastname: Sugiyama
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Yanaga
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ishikawa
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000378:metabolism* / Q000473:pathology*; D000328:Adult; D000818:Animals; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D001202:Ascitic Fluid / Q000166:cytology*; D014408:Biomarkers, Tumor / Q000032:analysis; D002166:Camptothecin / Q000031:analogs & derivatives / Q000494:pharmacology; D002272:Carcinoembryonic Antigen / Q000032:analysis; D045744:Cell Line, Tumor; D006063:Chorionic Gonadotropin / Q000378:metabolism*; D002945:Cisplatin / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D000077146:Irinotecan; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D017239:Paclitaxel / Q000494:pharmacology; D013004:Somatostatin / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000378:metabolism* / Q000473:pathology*
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D006063:Chorionic Gonadotropin; D013004:Somatostatin; D000077146:Irinotecan; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil; D002166:Camptothecin